Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.50 |
| ▸ | CDK2 | P24941 | 20/20 | 0.50 |
| ▸ | CCND1 | P24385 | 19/20 | 0.50 |
| ▸ | CDK6 | Q00534 | 19/20 | 0.50 |
| ▸ | CDK4 | P11802 | 5/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.50 |
| ▸ | CDK9 | P50750 | 5/20 | 0.50 |
| ▸ | CCND3 | P30281 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27034842 | 1.00 | CCNE1 (0.50) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30761998 | 0.87 | CCNE1 (0.50) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL27034846 | 0.87 | CCNE1 (0.50) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL27034843 | 0.86 | CCNE1 (0.48) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30761987 | 0.86 | CCNE1 (0.48) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30768112 | 0.85 | CDK2 (0.46) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL27033522 | 0.85 | CDK2 (0.46) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30761989 | 0.82 | CCNE1 (0.46) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL27060629 | 0.82 | CCNE1 (0.46) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30761965 | 0.81 | CCNE1 (0.44) | CCNE1CDK2CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4558502-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDKN1A, CDK8 | CCNE1 47/4885CDK2 7/4885CCND1 39/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | CCNE1 423/4885CDK2 1208/4885CCND1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.